IFNA2 and COVID-19: In this study, we report the presence of IgG autoantibodies that bind and neutralize the type I IFNs, IFNα2 and IFNω, in plasmas/sera and TBSs from approximately 10% of critically ill COVID-19 patients admitted to a tertiary ICU in Switzerland.